2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2378

Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 Months Despite Infrequent Use of Biologic Therapies
Abstract Number: 2589

EULAR Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice
Abstract Number: 1152

Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors
Abstract Number: 1174

Evaluating MRI-Detected Tenosynovitis of the Hand and Wrist in Early Arthritis
Abstract Number: 253

Evaluating Neuropathic Complaints By DN4 and Lanss Scales after Local Corticosteroid Therapy in Carpal Tunnel Syndrome
Abstract Number: 2336

Evaluating the Use of Video-Stimulated Recall to Research the Osteoarthritis Consultation in Primary Care: Reaching Parts Other Methods don’t Reach
Abstract Number: 1148

Evaluation of a Methodological Approach to Determine Timing of Rheumatoid Arthritis Disease Onset Using Administrative Claims Data
Abstract Number: 1177

Evaluation of a Simplified Version of the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Comprising 5 Joints (RAMRIS5)
Abstract Number: 1145

Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
Abstract Number: 563

Evaluation of Clinical Parameters and Quality of Life in Smokers with Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis
Abstract Number: 1558

Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response
Abstract Number: 917

Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab: Results from the Pivotal Phase 3 Fracture Study Extension
Abstract Number: 2852

Evaluation of KIR3DL1/KIR3DS1 Association with Behçet’s Disease in Turkish Individuals
Abstract Number: 137

Evaluation of Metalloproteinase-3 As a Soluble Biomarker of Synovitis Using Weighted Joint Counts Assessed Clinically and on Ultrasound Imaging
Abstract Number: 2402

Evaluation of Perceived Self-Efficacy, Learned Helplessness and Functional Capacity in Patients with Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].